EZH2 promotes progression of small cell lung cancer by suppressing the TGF-β-Smad-ASCL1 pathway

Transforming growth factor-β (TGF-β) induces apoptosis in many types of cancer cells and acts as a tumor suppressor. We performed a functional analysis of TGF-β signaling to identify a molecular mechanism that regulated survival in small cell lung cancer cells. Here, we found low expression of TGF-β type II receptor (TβRII) in most small cell lung cancer cells and tissues compared to normal lung epithelial cells and normal lung tissues, respectively. When wild-type TβRII was overexpressed in small cell lung cancer cells, TGF-β suppressed cell growth in vitro and tumor formation in vivo through induction of apoptosis. Components of polycomb repressive complex 2, including enhancer of zeste 2 (EZH2), were highly expressed in small cell lung cancer cells; this led to epigenetic silencing of TβRII expression and suppression of TGF-β-mediated apoptosis. Achaete-scute family bHLH transcription factor 1 (ASCL1; also known as ASH1), a Smad-dependent target of TGF-β, was found to induce survival in small cell lung cancer cells. Thus, EZH2 promoted small cell lung cancer progression by suppressing the TGF-β-Smad-ASCL1 pathway.

[1]  Kohei Miyazono,et al.  Thyroid transcription factor-1 inhibits transforming growth factor-beta-mediated epithelial-to-mesenchymal transition in lung adenocarcinoma cells. , 2009, Cancer research.

[2]  P. A. Sant'agnese,et al.  Neuroendocrine differentiation in prostatic carcinoma: an update on recent developments. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[3]  H. Moses,et al.  ©1999 Cancer Research Campaign Article no. bjoc.1998.0161 , 2022 .

[4]  S. Lippman,et al.  Lung cancer. , 2008, The New England journal of medicine.

[5]  M. Ohira,et al.  Oncogenic LMO3 Collaborates with HEN2 to Enhance Neuroblastoma Cell Growth through Transactivation of Mash1 , 2011, PloS one.

[6]  Debashis Ghosh,et al.  EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[7]  Douglas W. Ball,et al.  Notch Signaling Induces Rapid Degradation of Achaete-Scute Homolog 1 , 2002, Molecular and Cellular Biology.

[8]  Brian Bierie,et al.  TGF- and cancer , 2006 .

[9]  M Reiss,et al.  Frequent inactivation of the transforming growth factor beta type II receptor in small-cell lung carcinoma cells. , 1997, Oncology research.

[10]  Takanori Fujita,et al.  PRC2 overexpression and PRC2-target gene repression relating to poorer prognosis in small cell lung cancer , 2013, Scientific Reports.

[11]  H. Aburatani,et al.  A Smad3 and TTF-1/NKX2-1 complex regulates Smad4-independent gene expression , 2014, Cell Research.

[12]  H. Aburatani,et al.  Chromatin Immunoprecipitation on Microarray Analysis of Smad2/3 Binding Sites Reveals Roles of ETS1 and TFAP2A in Transforming Growth Factor β Signaling , 2008, Molecular and Cellular Biology.

[13]  Kohei Miyazono,et al.  TGFβ signalling: a complex web in cancer progression , 2010, Nature Reviews Cancer.

[14]  A. Berns,et al.  A functional role for tumor cell heterogeneity in a mouse model of small cell lung cancer. , 2011, Cancer cell.

[15]  K. Kinzler,et al.  Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability. , 1995, Science.

[16]  R. Derynck,et al.  SPECIFICITY AND VERSATILITY IN TGF-β SIGNALING THROUGH SMADS , 2005 .

[17]  G. Ganji,et al.  EZH 2 inhibition as a therapeutic strategy for lymphoma with EZH 2-activating mutations , 2012 .

[18]  Y. Yatabe,et al.  Molecular and Cellular Pathobiology Mir-375 Is Activated by Ash1 and Inhibits Yap1 in a Lineage-dependent Manner in Lung Cancer , 2022 .

[19]  P. Massion,et al.  Restoration of TGF-β signalling reduces tumorigenicity in human lung cancer cells , 2005, British Journal of Cancer.

[20]  Masaru Miyazaki,et al.  Aberrant expression of human achaete-scute homologue gene 1 in the gastrointestinal neuroendocrine carcinomas. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[21]  M. Chalhoub,et al.  Clinical Medicine Insights: Oncology R a P I D C O M M U N I C a T I O N Small Cell Lung Cancer Doubling Time and Its Effect on Clinical Presentation: a Concise Review , 2022 .

[22]  V. Keshamouni,et al.  Glycogene Expression Alterations Associated with Pancreatic Cancer Epithelial-Mesenchymal Transition in Complementary Model Systems , 2010, PloS one.

[23]  Derek Y. Chiang,et al.  Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. , 2009, Cancer research.

[24]  W. Franklin,et al.  Loss of Transforming Growth Factor Beta Type II Receptor Increases Aggressive Tumor Behavior and Reduces Survival in Lung Adenocarcinoma and Squamous Cell Carcinoma , 2012, Clinical Cancer Research.

[25]  K. Cibulskis,et al.  Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer , 2012, Nature Genetics.

[26]  H. Aburatani,et al.  Transforming growth factor-beta promotes survival of mammary carcinoma cells through induction of antiapoptotic transcription factor DEC1. , 2007, Cancer research.

[27]  F. Guillemot,et al.  A novel function of the proneural factor Ascl1 in progenitor proliferation identified by genome-wide characterization of its targets. , 2011, Genes & development.

[28]  Kohei Miyazono,et al.  TGF-β signalling from cell membrane to nucleus through SMAD proteins , 1997, Nature.

[29]  T. Enomoto,et al.  Mutational analysis of the transforming growth factor beta receptor type II gene in human ovarian carcinoma. , 1998, Cancer research.

[30]  J. Yokota,et al.  Infrequent mutations of the transforming growth factor beta-type II receptor gene at chromosome 3p22 in human lung cancers with chromosome 3p deletions. , 1997, Carcinogenesis.

[31]  K. Miyazono,et al.  Smad4 Decreases the Population of Pancreatic Cancer-Initiating Cells through Transcriptional Repression of ALDH1A1. , 2015, The American journal of pathology.

[32]  A. Moustakas,et al.  Actions of TGF-β as tumor suppressor and pro-metastatic factor in human cancer , 2007 .

[33]  R Wieser,et al.  Signaling activity of transforming growth factor beta type II receptors lacking specific domains in the cytoplasmic region , 1993, Molecular and cellular biology.

[34]  E. Greer,et al.  Histone methylation: a dynamic mark in health, disease and inheritance , 2012, Nature Reviews Genetics.

[35]  S. Markowitz,et al.  Molecular mechanisms of inactivation of TGF-β receptors during carcinogenesis , 2000 .

[36]  S. Baylin,et al.  An achaete-scute homologue essential for neuroendocrine differentiation in the lung , 1997, Nature.

[37]  D. Jackman,et al.  Small-cell lung cancer , 2005, The Lancet.

[38]  P. di Sant'Agnese,et al.  Neuroendocrine differentiation in prostatic carcinoma: an update on recent developments. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[39]  K. Miyazono,et al.  TGF-β-induced apoptosis of B-cell lymphoma Ramos cells through reduction of MS4A1/CD20 , 2013, Oncogene.

[40]  G. Berx,et al.  Regulatory networks defining EMT during cancer initiation and progression , 2013, Nature Reviews Cancer.

[41]  Tao Wang,et al.  ASCL1 is a lineage oncogene providing therapeutic targets for high-grade neuroendocrine lung cancers , 2014, Proceedings of the National Academy of Sciences.

[42]  H. Aburatani,et al.  Cell Type-specific Target Selection by Combinatorial Binding of Smad2/3 Proteins and Hepatocyte Nuclear Factor 4α in HepG2 Cells , 2011, The Journal of Biological Chemistry.

[43]  R. Kageyama,et al.  bHLH Factors in Self-Renewal, Multipotency, and Fate Choice of Neural Progenitor Cells , 2014, Neuron.

[44]  H. Aburatani,et al.  Transforming growth factor-β-induced lncRNA-Smad7 inhibits apoptosis of mouse breast cancer JygMC(A) cells , 2014, Cancer science.

[45]  Hitoshi Nomura,et al.  ASCL1-coexpression profiling but not single gene expression profiling defines lung adenocarcinomas of neuroendocrine nature with poor prognosis. , 2012, Lung cancer.

[46]  Xaralabos Varelas,et al.  The Transcriptional Regulators TAZ and YAP Direct Transforming Growth Factor β-induced Tumorigenic Phenotypes in Breast Cancer Cells*♦ , 2014, The Journal of Biological Chemistry.

[47]  Francesco Porpiglia,et al.  Human ASH1 expression in prostate cancer with neuroendocrine differentiation , 2008, Modern Pathology.

[48]  I. Screpanti,et al.  Proapoptotic function of the retinoblastoma tumor suppressor protein. , 2009, Cancer cell.

[49]  Samy Lamouille,et al.  TGF-β-induced epithelial to mesenchymal transition , 2009, Cell Research.

[50]  J. Massagué.  TGFβ Signaling: Receptors, Transducers, and Mad Proteins , 1996, Cell.

[51]  Shuichi Tsutsumi,et al.  ChIP-seq reveals cell type-specific binding patterns of BMP-specific Smads and a novel binding motif , 2011, Nucleic acids research.

[52]  K. Miyazono,et al.  Bone morphogenetic protein-2 and -4 play tumor suppressive roles in human diffuse-type gastric carcinoma. , 2011, The American journal of pathology.

[53]  Kristian Helin,et al.  Chromatin proteins and modifications as drug targets , 2013, Nature.

[54]  Yan Liu,et al.  EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations , 2012, Nature.

[55]  S. Novello,et al.  Lung cancer in never smokers: a different disease , 2014, Current Respiratory Care Reports.

[56]  S. Dhanasekaran,et al.  The polycomb group protein EZH2 is involved in progression of prostate cancer , 2002, Nature.

[57]  Kristian Helin,et al.  EZH2 is downstream of the pRB‐E2F pathway, essential for proliferation and amplified in cancer , 2003, The EMBO journal.

[58]  S. Chowdhury,et al.  Epigenetic Targeting of Transforming Growth Factor β Receptor II and Implications for Cancer Therapy. , 2009, Molecular and cellular pharmacology.

[59]  A. Berns,et al.  Induction of small cell lung cancer by somatic inactivation of both Trp53 and Rb1 in a conditional mouse model. , 2003, Cancer cell.

[60]  I. V. Kovtun,et al.  ASCL1 and RET expression defines a clinically relevant subgroup of lung adenocarcinoma characterized by neuroendocrine differentiation , 2014, Oncogene.

[61]  A. Berns,et al.  Cell of origin of small cell lung cancer: inactivation of Trp53 and Rb1 in distinct cell types of adult mouse lung. , 2011, Cancer cell.

[62]  A. Adjei,et al.  Small cell lung cancer. , 2008, Mayo Clinic proceedings.